Literature DB >> 3889175

Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.

R Sakulramrung, G J Domingue.   

Abstract

The potential immunoprotective role of antiserum to an Escherichia coli J5 mutant derived from E. coli O111:B4 was demonstrated in an experimental mouse model. Overwhelming bacterial inocula masked the effects of cross-reactive immunoprotection due to antiserum to strain J5. Enhanced bacterial clearance was observed in mice receiving antiserum to strain J5 in sublethal infections but not from lethal doses. Incorporation of hemoglobin with the bacterial inocula decreased the 50% lethal dose of challenge organisms, allowing the demonstration of protective activity of antiserum to strain J5 in lethal infection. Pretreatment of mice with antiserum to strain J5 did not protect against lethal doses of endotoxin. The protective factor was demonstrated by exhaustive adsorption experiments to be an antibody specific for strain J5 lipopolysaccharide. The protective activity of antiserum to strain J5 was abolished only after adsorption with strain J5 lipopolysaccharide but not with Salmonella typhimurium mutants with or without enterobacterial common antigen.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3889175     DOI: 10.1093/infdis/151.6.995

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Identification of the immunogenic outer membrane protein A antigen of Haemophilus parasuis by a proteomics approach and passive immunization with monoclonal antibodies in mice.

Authors:  Huabin Tian; Fang Fu; Xuesong Li; Xin Chen; Wei Wang; Yuekun Lang; Feng Cong; Changjun Liu; Guangzhi Tong; Xi Li
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

Review 3.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 4.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

5.  Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.

Authors:  J de Jongh-Leuvenink; J Schellekens; J Verhoef
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

6.  Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS.

Authors:  T Kato; I Takazoe; K Okuda
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

7.  Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin.

Authors:  D T Golenbock; J A Will; C R Raetz; R A Proctor
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

8.  Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.

Authors:  W C Bogard; D L Dunn; K Abernethy; C Kilgarriff; P C Kung
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

9.  Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.

Authors:  B J Appelmelk; A M Verwey-van Vught; J J Maaskant; W F Schouten; L G Thijs; D M Maclaren
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

10.  Lipid X protects mice against fatal Escherichia coli infection.

Authors:  D T Golenbock; J E Leggett; P Rasmussen; W A Craig; C R Raetz; R A Proctor
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.